OncoZenge AB intends to enter partnership with Pharmanovia for commercialization of BupiZenge™ in Europe, Middle East & North Africa Fri, Oct 18, 2024 10:00 CET Report this contentSTOCKHOLM, SWEDEN – October 18, 2024 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces the intention to partner with the global pharmaceutical leader Pharmanovia regarding exclusive rights to commercialization of BupiZenge™ in Europe, the Middle East, and Northern Africa (the “EMENA region”). The Company has signed a non-binding offer from Pharmanovia for a commercial partnership to introduce BupiZenge™ in Europe, the Middle East and Northern Africa. The intended agreement includes potential milestone payments, up to €7 million in support of the Phase 3 program and commercialization for BupiZenge™. We look forward to working with OncoZenge towards a definite agreement and on our mutual plans to ensure a successful clinical program and market introduction. The lead indication for BupiZenge™ is oral pain caused by oral mucositis, an inflammatory condition affecting millions of cancer patients.

Source: The North Africa Journal October 18, 2024 09:45 UTC